AI-guided first-line immunotherapy for liver cancer
Part of Cancer clinical trials.
This trial tests whether an artificial intelligence tool can help doctors choose the best first immunotherapy drug for people with advanced liver cancer that can't be removed by surgery. The goal is to see if AI-guided treatment selection leads to better outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of liver cancer called hepatocellular carcinoma that cannot be surgically removed.
- You have not had any prior systemic treatment (like chemotherapy or immunotherapy) for your liver cancer.
- Your liver function is good (Child-Pugh class A).
- You are able to get out of bed and care for yourself (ECOG performance status 0 or 1).
- Your doctor plans to start you on an immunotherapy-based drug as your first treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of liver-directed chemotherapy (HAIC) with the immunotherapy drugs atezolizumab and bevacizumab for people with liver cancer that cannot be surgically removed. It aims to see if this combination can shrink tumors and improve outcomes.
This trial tests whether an artificial intelligence system can help detect liver cancer recurrence earlier after curative treatment, allowing for potentially curative salvage therapy. Participants who have undergone complete surgical removal or ablation of their first liver cancer will be monitored with AI-assisted imaging.
This study uses artificial intelligence (AI) to analyze your CT or MRI scans and help predict how well immunotherapy might work for your liver cancer. The goal is to find better ways to match you with the right treatment and improve your outcomes.
This trial tests a new precision approach for people with liver cancer that cannot be removed by surgery. It uses a computer model to analyze your tumor and genetic information to see if combining HAIC (chemotherapy directly into the liver), lenvatinib (a targeted drug), and a PD-1 inhibitor (immunotherapy) is the right treatment for you.
This trial uses artificial intelligence to help doctors better stage (classify the severity of) and plan treatment for hepatocellular carcinoma, a type of primary liver cancer. Researchers will collect your clinical information and imaging to see if AI can improve decision-making about your care.
This Phase 2 study tests whether an artificial intelligence tool can help doctors choose the right dose for treating advanced hepatocellular carcinoma (HCC), a type of liver cancer. It aims to improve safety and effectiveness by matching treatment to you using your liver function, lab results, and treatment course.
Hear when a new Unresectable Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.